Understanding how certain enzymes affect the production of the Hepatitis B virus
Developmental regulation of HBV biosynthesis by Ten-eleven translocation (Tet) methylcytosine dioxygenases
This study is looking at how certain enzymes in the body affect the Hepatitis B virus and its ability to grow, with the hope of finding new ways to help people manage or even cure their HBV infections.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Illinois at Chicago NIH-funded |
| Lab location | 1 site (Chicago, UNITED STATES) |
| Project ID | NIH-11129627 on NIH RePORTER |
What this research studies
This research investigates the role of Ten-eleven translocation (Tet) enzymes in the biosynthesis of the Hepatitis B virus (HBV). By using specially developed mouse models, the study aims to understand how these enzymes influence the viral DNA's structure and its ability to replicate. The research focuses on the mechanisms that lead to chronic HBV infections and seeks to identify potential therapeutic targets that could lead to effective treatments. Patients may benefit from insights gained into how to better manage or potentially cure HBV infections.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals who are chronic carriers of Hepatitis B virus, particularly those experiencing acute liver disease.
Not a fit: Patients who do not have Hepatitis B virus infection or those with other unrelated liver conditions may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively eliminate chronic Hepatitis B infections.
How similar studies have performed: Previous research has shown promise in targeting viral biosynthesis mechanisms, suggesting that this approach could lead to significant advancements in HBV treatment.
Where this research is happening
Chicago, UNITED STATES
- University of Illinois at Chicago — Chicago, United States (Active)
Researchers
- Principal investigator: Mclachlan, Alan — University of Illinois at Chicago
- Study coordinator: Mclachlan, Alan
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.